Compare ATER & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATER | GDTC |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 12.4M |
| IPO Year | 2019 | 2021 |
| Metric | ATER | GDTC |
|---|---|---|
| Price | $1.21 | $1.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 11.1M | 14.4K |
| Earning Date | 05-14-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $68,975,000.00 | N/A |
| Revenue This Year | $16.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.52 | $0.68 |
| 52 Week High | $1.87 | $3.68 |
| Indicator | ATER | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 61.79 | 64.38 |
| Support Level | $0.61 | $0.93 |
| Resistance Level | $1.30 | $1.25 |
| Average True Range (ATR) | 0.15 | 0.11 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 67.32 | 72.18 |
Aterian Inc is a consumer products company that operates through online retail channels, including Amazon, Walmart, Target, as well as its own direct-to-consumer websites. The company develops and manages a portfolio of owned brands, which are either internally incubated or acquired, offering products across multiple categories such as home and kitchen appliances, kitchenware, air quality appliances, health and beauty products, and essential oils. Its primary brands include Squatty Potty, HomeLabs, Mueller Living, PurSteam, Healing Solutions, and Photo Paper Direct. The company generates revenue mainly through the online sale of its consumer products, with substantially all sales derived from the Amazon U.S. marketplace.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.